Educational Programs for You and Your Staff

Get the latest news on canine inappetence and ENTYCE® (capromorelin oral solution), the only FDA-approved veterinary therapeutic for stimulating appetite in dogs.

Conferences

Learn more about ENTYCE at Aratana Therapeutics educational sessions or by stopping by our booth at these upcoming conferences.

September 13-17

IVECCS 2018

September 13-17, 2018
New Orleans, LA

October 18-20

VCS

October 18-20, 2018
Louisville, KY

October 24-27

ACVS

October 24-27, 2018
Phoenix, AZ

November 8-9

New York Vet Conference

November 8-9, 2018
New York, NY

IMPORTANT SAFETY INFORMATION: ENTYCE® (capromorelin oral solution) is for use in dogs only. Do not use in breeding, pregnant or lactating dogs. Use with caution in dogs with hepatic dysfunction or renal insufficiency. Adverse reactions in dogs may include diarrhea, vomiting, polydipsia, and hypersalivation. Should not be used in dogs that have a hypersensitivity to capromorelin. Please see the full Prescribing Information for more detail.

Other therapeutics from Aratana

Nocita® (bupivacaine liposome injectable suspension)
NOCITA® (bupivacaine liposome injectable suspension) is the only long-acting local anesthetic that controls cranial cruciate ligament (CCL) post-op pain with one dose for up to 72 hours.

You can be sure that the local relief will help keep your patient is comfortable even after going home.

Visit Website >

IMPORTANT SAFETY INFORMATION: NOCITA® (bupivacaine liposome injectable suspension) is for use in dogs only. Do not use in dogs younger than 5 months of age, dogs used for breeding, or in pregnant or lactating dogs. Do not administer by intravenous or intra-arterial injection. Adverse reactions in dogs may include discharge from incision, incisional inflammation and vomiting. Avoid concurrent use with bupivacaine HCl, lidocaine or other amide local anesthetics. Please see the full Prescribing Information for more detail.